![Professor Claude Wischik Professor Claude Wischik](/img/200x200/staffpages/assets/images/default-profile-picture.jpg)
Professor Claude Wischik
Chair in Mental Health (Clin)
- About
-
- Email Address
- c.m.wischik@abdn.ac.uk
- Office Address
TauRx Therapeutics Ltd
1st Floor, Sir Moir Lockhead Building
395 King Street
Aberdeen
AB24 5RP
United Kingdom
- School/Department
- School of Medicine, Medical Sciences and Nutrition
- Research
-
Research Overview
Molecular Neuropathology of Alzheimer's Disease, and in particular the therapeutic intervention of tau pathology
- Publications
-
Page 2 of 2 Results 51 to 99 of 99
Monoaminergic Neuropathology in Alzheimer's disease
Progress in Neurobiology, vol. 151, pp. 101-138Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.pneurobio.2016.04.001
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/8480/1/ProgN_Simic.pdf
Distinct anatomical subtypes of behavioural variant frontotemporal dementia and involvement of intrinsic brain networks: a clustering study
Alzheimer Research UK (2017)Contributions to Conferences: AbstractsAssays for the Screening and Characterization of Tau Aggregation Inhibitors
Tau Protein: Methods and Protocols. Smet-Nocca, C. (ed.). Springer, pp. 129-140, 12 pagesChapters in Books, Reports and Conference Proceedings: Chapters- [ONLINE] DOI: https://doi.org/10.1007/978-1-4939-6598-4_8
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial
The Lancet, vol. 388, no. 10062, pp. 2873-2884Contributions to Journals: ArticlesInhibition of Tau Aggregation as a Basis for Treatment and Prevention of Alzheimer's Disease
Developing Therapeutics for Alzheimer's Disease: Progress and Challenges. Wolfe, M. S. (ed.). Elsevier Inc., pp. 385-436, 52 pagesChapters in Books, Reports and Conference Proceedings: Chapters- [ONLINE] DOI: https://doi.org/10.1016/B978-0-12-802173-6.00015-0
- [ONLINE] View publication in Scopus
Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease
Biomolecules, vol. 6, no. 2, pp. 1-19Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.3390/biom6020019
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/5864/1/biomolecules_06_00019_v2.pdf
Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies
Biomolecules, vol. 6, no. 1, 6Contributions to Journals: Review articles- [ONLINE] DOI: https://doi.org/10.3390/biom6010006
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/8985/1/biomolecules_06_00006_v2.pdf
- [ONLINE] View publication in Scopus
Neural correlates of cognitive and behavioural impairments in behavioural variant of frontotemporal dementia: A voxel based morphometry analysis
SINAPSE Annual Scientific Meeting (2016)Contributions to Conferences: AbstractsPhenothiazine compounds for treating mild cognitive impairment
Patents: PatentsDifferent pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer’s disease and frontotemporal lobar degeneration
Cellular and Molecular Life Sciences, vol. 72, no. 11, pp. 2199-2222Contributions to Journals: ArticlesEffects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models
Behavioural Pharmacology, vol. 26, no. 4, pp. 353-368Contributions to Journals: ArticlesCellular Models of Aggregation-Dependent Template-Directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer's Disease
The Journal of Biological Chemistry, vol. 290, no. 17, pp. 10862-10875Contributions to Journals: ArticlesThe relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer's disease
Frontiers in Neuroscience, vol. 9, 33Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.3389/fnins.2015.00033
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/4290/1/fnins_09_00033.pdf
Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease
Journal of Alzheimer's Disease, vol. 44, no. 2, pp. 705-720Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.3233/JAD-142874
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/4205/1/fulltext.pdf
Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease
Journal of Pharmacology and Experimental Therapeutics, vol. 352, no. 1, pp. 110-118Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1124/jpet.114.219352
Tau-aggregation inhibitor therapy for Alzheimer's disease
Biochemical Pharmacology, vol. 88, no. 4, pp. 529-539Contributions to Journals: ArticlesTauRx global phase 3 trial in Alzheimer's disease with tau aggregation inhibitor LMTX
13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, pp. S26Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1016/j.neurobiolaging.2014.01.128
New phenothiazine diaminium compounds are tau protein aggregation inhibitors, useful to treat e.g. Alzheimer's disease, Pick's disease, progressive supranuclear palsy, frontotemporal dementia and frontotemporal lobar degeneration syndromes
Patents: PatentsRegional cerebral blood flow and aberrant motor behaviour in Alzheimer's disease
Behavioural Brain Research, vol. 222, no. 2, pp. 375-379Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.bbr.2011.04.003
The cerebral blood flow correlates of emotional facial processing in mild Alzheimer's disease
Neuroscience & Medicine, vol. 2, no. 1, pp. 6-13Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.4236/nm.2011.21002
3,7-diamino-10H-phenothiazine salts and their use: WO2007110627
Patents: PatentsStripline resonator and preamplifier for preclinical magnetic resonance imaging at 4.7 T
Magnetic Resonance Materials in Physics, Biology and Medicine, vol. 24, no. 6, pp. 331-337Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1007/s10334-011-0273-8
3,6-Disubstituted xanthylium salts
Patents: PatentsMethods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC): methods of treatment of a tauopathy condition comprising the use of thioninium compounds
Patents: PatentsLigands for aggregated tau molecules: WO2010034982
Patents: PatentsRationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies
Emerging drugs and targets for Alzheimer's disease: Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism. Martinez, A. (ed.), pp. 210-232, 23 pagesChapters in Books, Reports and Conference Proceedings: Chapters- [ONLINE] DOI: https://doi.org/10.1039/9781849731065
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/4066/1/Wischik_2010_RSC_Chapter.pdf
Lewy body variant of Alzheimer's disease: selective neocortical loss of t-SNARE proteins and loss of MAP2 and alpha-synuclein in medial temporal lobe
The Scientific World Journal, vol. 9, pp. 1463-1475Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1100/tsw.2009.151
Therapeutic Use of Diaminophenothiazines: WO2009044127
Patents: PatentsMethylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine
Psychopharmacology, vol. 202, no. 1-3, pp. 53-65Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1007/s00213-008-1394-2
Methods of synthesis and/or purification of diaminophenothiazinium compounds
Patents: PatentsThiazin red as a neuropathological tool for the rapid diagnosis of Alzheimer's disease in tissue imprints
Acta Neuropathologica, vol. 116, no. 5, pp. 507-515Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1007/s00401-008-0431-x
Inhibitors of protein aggregation: WO2007110629
Patents: PatentsA55 A rCBF study of hallucinations in dementia.
Nuclear Medicine Communications, vol. 27, no. 3, 295Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1097/00006231-200603000-00066
Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC)
Patents: PatentsInhibition of tau-tau-association
Patents: PatentsAlzheimer's disease
The Oxford Companion to The Mind. Gregory, R. (ed.). 2 edition. Oxford University Press, pp. 24-27, 4 pagesChapters in Books, Reports and Conference Proceedings: ChaptersNaphthoquinone-type inhibitors of protein aggregation
Patents: PatentsMaterials and methods relating to protein aggregation in neurodegenerative disease: WO2002059150
Patents: PatentsLoss of synaptic but not cytoskeletal proteins in the cerebellum of chronic schizophrenics
Neuroscience Letters, vol. 317, no. 3, pp. 161-165Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/S0304-3940(01)02458-2
Inhibition of tau-tau-association
Patents: PatentsMaterials and methods relating to protein aggregation in neurodegenerative disease: WO2002055720
Patents: PatentsNeurofibrillary labels
Patents: PatentsAccumulation of C-terminally truncated tau protein associated with vulnerability of the perforant pathway in early stages of neurofibrillary pathology in Alzheimer’s disease
Journal of Chemical Neuroanatomy, vol. 22, no. 1-2, pp. 65-77Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/S0891-0618(01)00096-5
Loss of synaptic, but not cytoskeletal proteins in the cerebellum of people with chronic schizophrenia
Schizophrenia Research, vol. 49, no. Suppl. 1, pp. 55Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1016/S0920-9964(01)00159-1
The molecular basis of tau protein pathology in Alzheimer's Disease and related neurodegenerative dementias
Neurobiology of Alzheimer’s Disease. Dawbarn, D., Allen, S. (eds.). 2 edition. Oxford University PressChapters in Books, Reports and Conference Proceedings: ChaptersStaging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease
American Journal of Pathology, vol. 157, no. 2, pp. 623-636Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/S0002-9440(10)64573-7
α-Synuclein inclusions in Alzheimer and Lewy body diseases
Journal of Neuropathology and Experimental Neurology, vol. 59, no. 5, pp. 408-417Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1093/jnen/59.5.408
- [ONLINE] View publication in Scopus
The extent of neurofibrillary pathology in perforant pathway neurons is the key determinant of dementia in the very old
Acta Neuropathologica, vol. 100, pp. 29-35Contributions to Journals: Articlesalpha-synuclein inclusions in Alzheimer and Lewy body diseases
Journal of Neuropathology and Experimental Neurology, vol. 59, pp. 408-417Contributions to Journals: Articles